Disease-modifying therapy in progressive multiple sclerosis: a systematic review and network meta-analysis of randomized controlled trials - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38529035/
https://inplasy.com/?s=202320071, identifier: 202320071.
This systematic review evaluates the efficacy and safety of disease-modifying therapies for progressive multiple sclerosis, finding mitoxantrone, siponimod, and ocrelizumab most effective in delaying progression and mitigating disability.
Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39379875/
Limitations of these analyses included the potential for confounding due to pseudoatrophy, and a lack of long-term clinical data for BVL. Our findings suggest that important differences in BVL may...
This study reviewed randomized trials on disease-modifying therapies (DMTs) in relapsing multiple sclerosis (RMS), highlighting significant differences in brain volume loss (BVL) reduction, emphasizing the need for further BVL-focused research.
Comparative immunogenicity assessment of biosimilar natalizumab to its reference medicine: a matching immunogenicity profile - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39749348/
The immunogenicity profile of biosim-NTZ was confirmed to match that of ref-NTZ in healthy subjects and patients with RRMS by applying highly sensitive methods.
Biosimilar natalizumab demonstrated matching immunogenicity to reference natalizumab in RRMS patients and healthy subjects, with similar ADA/NAb incidence and titers, confirming biosimilarity using highly sensitive bioanalytical assays.
Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39393045/
ClinicalTrials.gov, NCT03689972; EudraCT, 2018-002145-11. Submitted 2018-09-27. First patient enrolled: 2018-12-26. https://clinicaltrials.gov/study/NCT03689972.
Extended-interval natalizumab dosing (Q6W) reduced PML risk while maintaining efficacy in most RRMS patients. Q6W decreased trough drug levels and α4-integrin saturation but did not consistently predict lesion or relapse activity.
Histoplasmosis in a fingolimod-treated patient: case report and scoping review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39052026/
Fingolimod is a sphingosine-1-phosphate receptor modulator used to treat multiple sclerosis. While fingolimod has been associated with an increased risk of cryptococcal meningitis, its correlation with other deep mycoses remains...
Fingolimod therapy for multiple sclerosis may increase the risk of disseminated histoplasmosis, especially in endemic regions. Prompt diagnosis, itraconazole treatment, and adjusting immunotherapy yield favorable outcomes.